KR920700206A - 테트라-아자 마크로싸이클 화합물과 이들의 금속착화합물 - Google Patents
테트라-아자 마크로싸이클 화합물과 이들의 금속착화합물Info
- Publication number
- KR920700206A KR920700206A KR1019890700624A KR890700624A KR920700206A KR 920700206 A KR920700206 A KR 920700206A KR 1019890700624 A KR1019890700624 A KR 1019890700624A KR 890700624 A KR890700624 A KR 890700624A KR 920700206 A KR920700206 A KR 920700206A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- group
- formula
- integer
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65G—TRANSPORT OR STORAGE DEVICES, e.g. CONVEYORS FOR LOADING OR TIPPING, SHOP CONVEYOR SYSTEMS OR PNEUMATIC TUBE CONVEYORS
- B65G49/00—Conveying systems characterised by their application for specified purposes not otherwise provided for
- B65G49/05—Conveying systems characterised by their application for specified purposes not otherwise provided for for fragile or damageable materials or articles
- B65G49/06—Conveying systems characterised by their application for specified purposes not otherwise provided for for fragile or damageable materials or articles for fragile sheets, e.g. glass
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Cephalosporin Compounds (AREA)
- External Artificial Organs (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (18)
- 구조식(1)의 화합물과 이의 금속착화합물 및 염.여기에서, m과 n은 0이거나 1, 2또는 3인 정수로 각각은 서로 같거나 상이할 수 있으며; b는 0 또는 1, 2또는 3인 정수;R, R1, R2와 R3는 수소원자 또는 알킬, 알콕시알킬, -CO2H, -SO3H, -PO2H2나 아릴기로 각각은 서로 같거나 상이할수 있으며; L은 공유결합 또는 연결기이고, Z는 수소원자 또는 반응성 관능기로, L이 공유결합이면 Z는 반응성 관능기이다.
- 제1항에 있어서, q는 1 내지 6인 정수이고,R, R1, R2와 R3가 -CO2H기인 화합물.
- 제2항에 있어서, q는 1인 화합물.
- 전술한 어느 한 항에 있어서, L은 임의로 치환된 지방족 하이드로카르빌 사슬과, -O-또는 -S-로부터 선택된 하나 또는 그 이상의 이종 원자에 의하여 임의로 차단되거나 또는 하나 또는 그 이상의 -N(R5)-(여기에서 R5는 수소원자나 C1-6알킬기), -CON(R5)-, N(R5)CO-, 시클로지방족, 방향족 혹은 헤테로 방향족기들에 의하여 임의로 차단된 것인 화합물.
- 전술한 어느 한 항에 있어서, Z가 티올, 아미노, 카르복실, 하이드록실, 알데히드, 방향족 또는 헤테로방향족기와 반응할 수 있는 것인 화합물.
- 제5항에 있어서, Z는 할로겐 원자 또는 -SH, -NH2, 하이드라진 또는 그 유도체, -NCO, -NCS, -COR10(여기에서 R10은 할로겐원자 또는 N3, C1-6알콕시, C6-12아릴옥시, 이미딜옥시 혹은 이미다 조일옥시기이다.), 이미드, -Het1-C(Het2)=CH2(여기에서 Het1과 Het2는 같거나 상이할 수도 있는 질소함유 헤테로시클릭기 이거나, Het1은 질소 함유 헤테로시클릭기이고 Het2는 수소원자 이다.) 또는 구조식(여기에서 R11은 C1-4알킬기이다)으로 구성된 군으로부터 선택된 것인 화합물.
- 금속의 이온가가 +2가 또는 +3가이고 배위수가 6 또는 그 이상의 금속이 착화된 전술한 항에서 언급한 구조식(1)화합물의 금속착화합물.
- 제7항에 있어서, 금속이 구리, 납, 비스무스, 이트륨, 테르븀, 가돌리늄 또는 스탄듐인 화합물.
- 특허청구의 범위 제1항 내지 제7항에서 언급한 구조식(1)화합물의 이트륨착화합물.
- 전술한 어느 한항에 있어서, d가 1인 화합물.
- 구조식 (1a)화합물과 이의 금속착화합물 및 염.여기에서 R1, R2와 R3는 수소원자 또는 알킬, 알콕시알킬, -CO2H, -SO3H, -PO2H2혹은 아릴기로 서로 같거나 다를수 있으며; L은 공유결합 또는 연결기; Z는 수소원자 또는 반응성관능기로서 L이 공유결합이면 Z는 반응성 관능기이다.
- 제11항에 있어서, R1, R2와 R3는 각각이 -CO2H기인 화합물.
- 구조식(1)화합물이나 금속착화합물 및 이들의 염이 단백질, 펩타이드 혹은 탄수화물과 결합된 공액화합물(conjugated compound).여기에서, m과 n은 0 또는 1, 2 또는 3인 정수로 서로 같거나 다를수 있으며; d는 0 또는 1, 2 또는 3인 정수; q는 0 또는 1 내지 6인 정수; R, R1, R2와 R3는 수소원자 또는 알킬, 알콕시알킬, -CO2H, -SO3H, -PO2H2또는 아릴기로 서로 같거나 다를수 있으며; L은 공유결합 또는 연결기; Z는 수소원자 또는 반응성 관능기로, L이 공유결합이면 Z는 반응성 관능기이다.
- 구조식(2)의 공액화합물(conjugated compound)과 이의 금속착화합물 및 이들의 염.여기에서, m과 n은 0 또는 1, 2 또는 3인 정수로 서로 같거나 다를수 있으며, d는 0 또는 1, 2 또는 3인 정수; q는 0 또는 1내지 6인 정수이며, R, R1, R2와 R3는 수소원자 또는 알킬, 알콕시 알킬, -CO3H, -SO3H, -PO2H2또는 아릴기로 서로 같거나 다를수 있으며; L은 공유결합 또는 연결기; Z1는 반응성관능기의 잔기; W는 0또는 1인 정수; z는 그이상의 정수; Ab는 항체이다.
- 특허청구의 범위 1항기재의 구조식(1)화합물이나 이들의 금속착화합물 또는 이들의 염과 하나또는 그 이상의 약학적으로 유용한 담체들로 구성된 조성물.
- 특허청구의 범위 제14항 기재의 구조식(2)화합물이나 이들의 금속착화합물 또는 이들의 염과 하나 이상의 약학적으로 유용한 담체들로 구성된 조성물.
- 구조식(3)화합물(여기에서 m, n, d, L과 Z는 구조식(1)의 화합물의 기재와 같다)이나 이들의 금속 착화합물을 R1(CH2)qD(여기에서 D는 치환기이고 R1과 q는 구조식(1)화합물의 기재와 같다.)인 시약과 반응시킴을 특징으로 하는 특허청구의 번위 제1항기재의 구조식(1)화합물 이들의 금속착화합물의 제조방법.
- 특허청구의 범위 제1항기재의 구조식(1)의 화합물을 항체 Ab와 반응시킴을 특징으로 하는 특허청구의 범위 제14항 기재의 구조식(2)의 공액화합물(conjugated compound)의 제조방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8719042 | 1987-08-12 | ||
GB878719042A GB8719042D0 (en) | 1987-08-12 | 1987-08-12 | Conjugate compounds |
PCT/GB1988/000671 WO1989001476A1 (en) | 1987-08-12 | 1988-08-12 | Tetra-aza macrocycles and metal complexes thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR920700206A true KR920700206A (ko) | 1992-02-19 |
Family
ID=10622173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019890700624A KR920700206A (ko) | 1987-08-12 | 1988-08-12 | 테트라-아자 마크로싸이클 화합물과 이들의 금속착화합물 |
Country Status (11)
Country | Link |
---|---|
US (1) | US6774228B1 (ko) |
EP (1) | EP0328589B1 (ko) |
JP (1) | JPH02501141A (ko) |
KR (1) | KR920700206A (ko) |
AT (1) | ATE136302T1 (ko) |
AU (1) | AU629515B2 (ko) |
CA (1) | CA1341102C (ko) |
DE (1) | DE3855177T2 (ko) |
DK (1) | DK172789A (ko) |
GB (1) | GB8719042D0 (ko) |
WO (1) | WO1989001476A1 (ko) |
Families Citing this family (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5422096A (en) * | 1985-05-08 | 1995-06-06 | The General Hospital Corporation | Hydroxy-aryl metal chelates for diagnostic NMR imaging |
US5250285A (en) * | 1985-05-08 | 1993-10-05 | The General Hospital Corporation | Hydroxy-aryl metal chelates for diagnostic NMR imaging |
US5271927A (en) * | 1986-02-13 | 1993-12-21 | Celltech Limited | Antibody conjugates with macrocyclic ligands |
US5132409A (en) * | 1987-01-12 | 1992-07-21 | Bracco Industria Chimica S.P.A. | Macrocyclic chelating agents and chelates thereof |
FR2614020B1 (fr) * | 1987-04-14 | 1989-07-28 | Guerbet Sa | Nouveaux ligands cycliques azotes, complexes metalliques formes par ces ligands, compositions de diagnostic contenant ces complexes et procede de preparation des ligands. |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8719041D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
RU2059642C1 (ru) * | 1987-12-24 | 1996-05-10 | Бракко Индустрия Кимика С.п.А | Хелаты гадолиния и способ их получения |
AU630362B2 (en) * | 1988-05-25 | 1992-10-29 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Macrocyclic chelates & methods of use thereof |
EP0353450B1 (en) * | 1988-06-24 | 1995-03-29 | The Dow Chemical Company | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates |
US5776894A (en) * | 1988-12-05 | 1998-07-07 | Novartis Ag | Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors |
US5342936A (en) * | 1989-02-10 | 1994-08-30 | David Parker | Tetra-aza macrocycles and processes for their preparation |
WO1990009379A1 (en) * | 1989-02-10 | 1990-08-23 | Celltech Limited | Aza-macrocycles and processes for their preparation |
US5053503A (en) * | 1989-02-17 | 1991-10-01 | Centocor | Chelating agents |
US6139603A (en) * | 1989-02-22 | 2000-10-31 | L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | Process for recovering oxygen |
DE3911816A1 (de) * | 1989-04-11 | 1990-10-25 | Hoechst Ag | Substituierte 1,4,7,10-tetraazacyclotridecane, verfahren zu deren herstellung sowie verwendung derselben zur markierung von substanzen mit radionukliden |
DK169306B1 (da) * | 1989-06-14 | 1994-10-10 | Af 18 Juni 1990 As | Middel til fjernelse eller inaktivering af uønskede komponenter i blod eller andre ekstracellulære legemsvæsker samt fremgangsmåde til fremstilling af dextran-O-carbonyl-benzo-18-crown-6 og af dextran-hydroxyethylbenzo-18-crown-6 |
US5247077A (en) * | 1989-06-23 | 1993-09-21 | Celltech Limited | Tri-aza macrocycles and processes for their preparation |
DE69032761T2 (de) * | 1989-08-28 | 1999-04-22 | Gen Hospital Corp | Hydroxy-aryl metallchelate für bildformung zur nmr diagnose |
FR2654102B1 (fr) * | 1989-11-09 | 1992-01-10 | Air Liquide | Procede de synthese de derives polyazotes cycliques. |
US5236695A (en) * | 1989-11-27 | 1993-08-17 | Concat, Ltd. | MRI image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands |
GB9004017D0 (en) * | 1990-02-22 | 1990-04-18 | Krenning Eric P | Improvements in or relating to organic compounds |
US5684135A (en) * | 1990-04-18 | 1997-11-04 | Celltech Therapeutics Limited | Conjugate compounds containing aza-macro-cycles and processes for their preparation |
GB9008724D0 (en) * | 1990-04-18 | 1990-06-13 | Celltech Ltd | Chemical compounds |
DE69124132T2 (de) * | 1990-04-18 | 1997-06-05 | Celltech Therapeutics Ltd | Tetra-aza-makrozyklen, Verfahren zu ihrer Herstellung und ihre Anwendung in NMR-Bildformung |
JPH06340556A (ja) * | 1990-06-18 | 1994-12-13 | Dow Chem Co:The | イメージング剤としての大環状アミノホスホン酸錯体の使用 |
GB9112536D0 (en) * | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
DE4237943C2 (de) * | 1992-11-06 | 1997-10-23 | Schering Ag | Verfahren zur Herstellung von Metallkomplexen der N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecan- und N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivate |
US5310535A (en) * | 1992-04-24 | 1994-05-10 | The Dow Chemical Company | Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies |
US5807535A (en) * | 1992-07-31 | 1998-09-15 | Australian Nuclear Science & Technology Organisation | Metal complexes of hydroxyaryl containing aminocarboxylic acid chelating agents |
PT590766E (pt) * | 1992-07-31 | 2000-07-31 | Australian Nuclear Science Tec | Complexos metalicos de hidroxiarilo contendo agentes quelantes de acido aminocarboxilico |
EP0588229A3 (en) * | 1992-09-12 | 1994-06-15 | Hoechst Ag | Macrocyclic chelating agents for the preparation of technetium or rhenium complexes |
CA2163232A1 (en) | 1993-05-20 | 1994-12-08 | Robert C. Brasch | Macromolecular contrast media for mr imaging |
US5582814A (en) * | 1994-04-15 | 1996-12-10 | Metasyn, Inc. | 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging |
TW319763B (ko) | 1995-02-01 | 1997-11-11 | Epix Medical Inc | |
GB9504910D0 (en) * | 1995-03-10 | 1995-04-26 | Nycomed Imaging As | Compounds |
US5874573A (en) | 1995-06-26 | 1999-02-23 | Concat, Inc. | Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
DE69942782D1 (de) | 1998-11-27 | 2010-10-28 | Ucb Sa | Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung |
US6565828B2 (en) * | 2000-04-07 | 2003-05-20 | Bristol-Myers Squibb Company | Macrocyclic chelants for metallopharmaceuticals |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
US6517814B2 (en) | 2001-01-09 | 2003-02-11 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants useful for metallopharmaceuticals |
JP2004530654A (ja) | 2001-02-23 | 2004-10-07 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | アテローム硬化症および脆弱性プラークを画像診断するための標識マクロファージスカベンジャー受容体拮抗薬 |
DE10135356C1 (de) | 2001-07-20 | 2003-04-17 | Schering Ag | Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen |
US7338651B2 (en) * | 2001-09-04 | 2008-03-04 | Texas Tech University System | Multi-use multimodal imaging chelates |
GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
JP4418745B2 (ja) | 2002-05-28 | 2010-02-24 | ユセベ ファルマ ソシエテ アノニム | 抗体peg位置異性体、それを含む組成物及びその使用 |
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
CN100418957C (zh) * | 2003-07-08 | 2008-09-17 | 香港大学 | 三-n-烷基化的1,4,7,10-四氮杂环十二烷的合成 |
CA2581639C (en) | 2004-09-30 | 2016-07-26 | Molecular Devices Corporation | Luminescent lanthanide complexes |
ZA200804594B (en) | 2005-12-09 | 2010-08-25 | Ucb Pharma Sa | Antibody molecules having specificity for human IL-6 |
JP2009529917A (ja) | 2006-03-22 | 2009-08-27 | ヴァイラル ロジック システムズ テクノロジー コーポレーション | 標的ポリペプチドの同定方法および免疫学的疾患の治療のためのその使用 |
US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
PL2398498T3 (pl) | 2009-02-17 | 2019-03-29 | Ucb Biopharma Sprl | Cząsteczki przeciwciał swoiste wobec ludzkiego OX40 |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB0920324D0 (en) | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
GB201000588D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
WO2011110604A1 (en) | 2010-03-11 | 2011-09-15 | Ucb Pharma, S.A. | Pd-1 antibody |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
US10472426B2 (en) | 2010-03-25 | 2019-11-12 | Ucb Biopharma Sprl | Disulfide stabilized DVD-Ig molecules |
GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
ES2632583T3 (es) | 2011-01-14 | 2017-09-14 | Ucb Biopharma Sprl | Anticuerpo que se une a IL-17A e IL-17F |
EP2546267A1 (en) | 2011-07-13 | 2013-01-16 | UCB Pharma S.A. | Bacterial host strain expressing recombinant DsbC |
MX2014002769A (es) | 2011-09-16 | 2014-06-11 | Ucb Pharma Sa | Anticuerpos neutralizantes para las exotoxinas principales tcda y tcdb de clostridium difficile. |
UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
GB201203071D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
WO2016176656A2 (en) | 2015-04-30 | 2016-11-03 | President And Fellows Of Harvard College | Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders |
GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
US10316097B2 (en) | 2015-05-27 | 2019-06-11 | Ucb Biopharma Sprl | Method for the treatment of epilepsy, epileptogenesis, seizures or convulsions by an anti-colony-stimulating factor 1 receptor (CSF-1R) antibody |
BR112017028102A2 (pt) | 2015-07-06 | 2018-09-04 | Ucb Biopharma Sprl | anticorpos de ligação à tau |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
MX2018005031A (es) | 2015-10-27 | 2018-06-13 | Ucb Biopharma Sprl | Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f). |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
EP3463482B1 (en) | 2016-06-07 | 2021-10-06 | The Brigham and Women's Hospital, Inc. | Methods relating to t peripheral helper cells in autoantibody-associated conditions |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
SG10201913858WA (en) | 2016-08-26 | 2020-03-30 | Agency Science Tech & Res | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof |
GB201616596D0 (en) | 2016-09-29 | 2016-11-16 | Nascient Limited | Epitope and antibodies |
GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
AU2018269039A1 (en) | 2017-05-19 | 2019-12-19 | Syndax Pharmaceuticals, Inc. | Combination therapies |
GB201802486D0 (en) | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
AU2019361247A1 (en) | 2018-10-16 | 2021-05-27 | UCB Biopharma SRL | Method for the treatment of Myasthenia Gravis |
SG11202109545VA (en) | 2019-03-26 | 2021-10-28 | Aslan Pharmaceuticals Pte Ltd | Treatment employing anti-il-13r antibody or binding fragment thereof |
GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
GB202001447D0 (en) | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
EP4229086A1 (en) | 2020-10-15 | 2023-08-23 | UCB Biopharma SRL | Binding molecules that multimerise cd45 |
WO2022089767A1 (en) | 2020-11-02 | 2022-05-05 | UCB Biopharma SRL | Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders |
EP4255925A1 (en) | 2020-12-07 | 2023-10-11 | UCB Biopharma SRL | Antibodies against interleukin-22 |
US20240067758A1 (en) | 2020-12-07 | 2024-02-29 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
WO2022186773A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION |
WO2022186772A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
EP4067381A1 (en) | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Novel tnfr2 binding molecules |
CA3218933A1 (en) | 2021-05-03 | 2022-11-10 | UCB Biopharma SRL | Antibodies |
GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
WO2023048650A1 (en) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
WO2023048651A1 (en) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | Method for treatment of moderate to severe atoptic dematitis |
GB202115122D0 (en) | 2021-10-21 | 2021-12-08 | Dualyx Nv | Binding molecules targeting IL-2 receptor |
TW202333784A (zh) | 2021-10-29 | 2023-09-01 | 新加坡商亞獅康私人有限公司 | 抗il13r抗體調配物 |
WO2023140780A1 (en) | 2022-01-24 | 2023-07-27 | Aslan Pharmaceuticals Pte Ltd. | Method of treating inflammatory disease |
WO2023163659A1 (en) | 2022-02-23 | 2023-08-31 | Aslan Pharmaceuticals Pte Ltd | Glycosylated form of anti-il13r antibody |
GB202210679D0 (en) | 2022-07-21 | 2022-09-07 | Dualyx Nv | Binding molecules targeting il-12rb2 |
WO2024043837A1 (en) | 2022-08-26 | 2024-02-29 | Aslan Pharmaceuticals Pte Ltd | High concentration anti-il13r antibody formulation |
WO2024054157A1 (en) | 2022-09-06 | 2024-03-14 | Aslan Pharmaceuticals Pte Ltd | Treatment for sleep loss or sleep disturbance in patients with dermatitis |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2803528C2 (de) * | 1977-03-09 | 1984-10-18 | Tabushi, Iwao, Kyoto | Schwermetallionen-Adsorbens und dessen Verwendung zum Adsorbieren von Schwermetallionen |
JPS53144592A (en) | 1977-05-19 | 1978-12-15 | Tabuse Iwao | 122alkyll1*4*7*100tetrazacyclotridecane |
US4432907A (en) | 1979-09-10 | 1984-02-21 | Analytical Radiation Corporation | Diamine acid fluorescent chelates |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
SU1098937A1 (ru) * | 1983-03-25 | 1984-06-23 | Ордена Ленина институт элементоорганических соединений им.А.Н.Несмеянова | 1,4,7,10-Тетра/диоксифосфорилметил/-1,4,7,10-тетраазациклододекан в качестве комплексона дл св зывани катионов меди /п/,кобальта /п/,кадми /п/,свинца /п/ и лантана /ш/ |
CA1260827A (en) | 1984-08-31 | 1989-09-26 | Richard C. Siegel | Antibody-metal ion complexes |
US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
ATE66469T1 (de) | 1985-01-14 | 1991-09-15 | Neorx Corp | Metall-radionuklid markiertes protein fuer diagnose und therapie. |
JPS61226751A (ja) | 1985-03-30 | 1986-10-08 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀写真感光材料用処理液及びその処理方法 |
US4678667A (en) | 1985-07-02 | 1987-07-07 | 501 Regents of the University of California | Macrocyclic bifunctional chelating agents |
US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
EP0232751B1 (en) | 1986-01-23 | 1991-09-11 | E.R. Squibb & Sons, Inc. | 1-substituted-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
GB8603537D0 (en) * | 1986-02-13 | 1986-03-19 | Parker D | Conjugate compound |
FR2596992B1 (fr) * | 1986-04-11 | 1988-12-16 | Guerbet Sa | Sel de lysine du complexe gadolinium-dota et ses applications au diagnostic |
DE3625417C2 (de) * | 1986-07-28 | 1998-10-08 | Schering Ag | Tetraazacyclododecan-Derivate |
GB8618443D0 (en) | 1986-07-29 | 1986-09-03 | Univ London | Monoclonal antibodies |
US5049667A (en) * | 1987-04-14 | 1991-09-17 | Guerbet S.A. | Nitrogen-containing cyclic ligands |
FR2614020B1 (fr) * | 1987-04-14 | 1989-07-28 | Guerbet Sa | Nouveaux ligands cycliques azotes, complexes metalliques formes par ces ligands, compositions de diagnostic contenant ces complexes et procede de preparation des ligands. |
DE3713842A1 (de) * | 1987-04-22 | 1988-11-17 | Schering Ag | Substituierte cyclische komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel |
AU617338B2 (en) * | 1987-07-16 | 1991-11-28 | Nycomed As | Aminopolycarboxylic acids and derivatives thereof |
ATE137228T1 (de) | 1987-07-16 | 1996-05-15 | Nycomed Imaging As | Aminocarbonsäure und derivate |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
JPH02500566A (ja) * | 1987-08-17 | 1990-03-01 | プラント・ジェネティック・システムズ・エヌ・ブイ | バチルス・スリンギエンシスからのdna配列で形質転換された植物 |
AU630362B2 (en) * | 1988-05-25 | 1992-10-29 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Macrocyclic chelates & methods of use thereof |
US4923985A (en) * | 1988-05-25 | 1990-05-08 | The United States Of America As Represented By The Department Of Health & Human Services | Process for synthesizing macrocyclic chelates |
US5053503A (en) * | 1989-02-17 | 1991-10-01 | Centocor | Chelating agents |
DE10135356C1 (de) * | 2001-07-20 | 2003-04-17 | Schering Ag | Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen |
-
1987
- 1987-08-12 GB GB878719042A patent/GB8719042D0/en active Pending
-
1988
- 1988-08-12 KR KR1019890700624A patent/KR920700206A/ko not_active Application Discontinuation
- 1988-08-12 AU AU22533/88A patent/AU629515B2/en not_active Ceased
- 1988-08-12 CA CA000574630A patent/CA1341102C/en not_active Expired - Fee Related
- 1988-08-12 AT AT88906975T patent/ATE136302T1/de not_active IP Right Cessation
- 1988-08-12 DE DE3855177T patent/DE3855177T2/de not_active Expired - Fee Related
- 1988-08-12 EP EP88906975A patent/EP0328589B1/en not_active Expired - Lifetime
- 1988-08-12 JP JP63506686A patent/JPH02501141A/ja active Pending
- 1988-08-12 WO PCT/GB1988/000671 patent/WO1989001476A1/en active IP Right Grant
-
1989
- 1989-04-11 DK DK172789A patent/DK172789A/da not_active IP Right Cessation
-
1990
- 1990-08-31 US US07/577,072 patent/US6774228B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0328589B1 (en) | 1996-04-03 |
AU629515B2 (en) | 1992-10-08 |
EP0328589A1 (en) | 1989-08-23 |
GB8719042D0 (en) | 1987-09-16 |
WO1989001476A1 (en) | 1989-02-23 |
DE3855177D1 (de) | 1996-05-09 |
DE3855177T2 (de) | 1996-10-02 |
AU2253388A (en) | 1989-03-09 |
DK172789D0 (da) | 1989-04-11 |
US6774228B1 (en) | 2004-08-10 |
JPH02501141A (ja) | 1990-04-19 |
ATE136302T1 (de) | 1996-04-15 |
DK172789A (da) | 1989-04-11 |
CA1341102C (en) | 2000-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920700206A (ko) | 테트라-아자 마크로싸이클 화합물과 이들의 금속착화합물 | |
KR920700205A (ko) | 트리-아자 마크로싸이클 화합물과 이들의 금속착화합물 | |
CA1288197C (en) | Metal ion labeling of carrier molecules | |
Sugiura et al. | Selenium protection against mercury toxicity: high binding affinity of methylmercury by selenium-containing ligands in comparison with sulfur-containing ligands | |
ATE67679T1 (de) | Einen makrozyklischen koordinat und einen antikoerper enthaltende konjugatverbindung. | |
KR910009786A (ko) | 착화합물, 이의 착물 및 콘쥬게이드가 결합된 캐스케이드 중합체, 이의 제조방법, 및 이들을 함유하는 약제학적 제제 | |
Vortisch et al. | Model studies on the coordination of copper in enzymes. IV. Structure and stability of cuprous complexes with sulfur-containing ligands | |
CA2095615A1 (en) | Polyazamacrocyclic compounds for complexation of metal ions | |
DK0452858T3 (da) | Til mærkning af proteiner og andre aminholdige forbindelser nyttige metalkomplekser af syreaddukter til dioximligander | |
KR880012572A (ko) | 질소함유 고리형 배위자의 제조방법 | |
CA1340665C (en) | Bifunctional coupling agents and radionuclide labeled compositions prepared therefrom | |
ATE199373T1 (de) | Aminoalkylmaleimide und davon abgeleitete hapten- und antigenderivate sowie konjugate mit peptiden oder proteinen | |
CA1293258C (en) | Biotinylating agents | |
US5294717A (en) | Bifunctional chelating agents, their chelates and process of preparation | |
CA2503647A1 (en) | Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof | |
Ryan et al. | Covalent linkage of ruthenium polypyridyl compounds to poly (L-lysine), albumins, and immunoglobulin G | |
Hojo et al. | Organomercury complexes of penicillamine and some other sulfur-containing ligands | |
CA1224718A (en) | Anti-cancer drugs comprising platinum complexes | |
JPS5616417A (en) | Antitumor protein complex and its preparation | |
Powers et al. | Intervalence transfer in the pyrimidine-bridged dimer [(bpy) 2ClRu (pym) RuCl (bpy) 2] 3+ | |
FR2616663B1 (fr) | Nouveaux tripeptides a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
KR920701127A (ko) | 단백질에 금속 이온을 부착하기 위한 킬레이트제 | |
DK0433457T3 (da) | Kløstillende præparat | |
MY133949A (en) | ANSA GROUP 4 METAL BIS (µ-SUBSTITUTED) ALUMINUM METALLOCENES. | |
Isab et al. | The redox reaction of gold (I)-thiomalate in the presence of selenourea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |